Tong Joo (TJ) Gan was named division head of Anesthesiology, Critical Care, and Pain Medicine at The University of Texas MD Anderson Cancer Center.
Researchers at The University of Texas MD Anderson Cancer Center identified a strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6.
MD Anderson, Community Health Network announce partnership to create fully integrated cancer program
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network announced a partnership agreement to create Community Health Network MD Anderson Cancer Center.
Ranna Parekh was named chief diversity, equity, and inclusion officer at The University of Texas MD Anderson Cancer Center, effective May 31.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer, researchers from The University of Texas MD Anderson Cancer Center reported at the 2022 AACR annual meeting.
Researchers at The University of Texas MD Anderson Cancer Center have developed a bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations. In retrospective validation studies, the tool selected combinations that resulted in improved patient outcomes across both pre-clinical and clinical studies.
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.
James Allison has reshaped cancer drug development, making checkpoint inhibitors a staple of therapy in many key indications—and dramatically improving survival outcomes in previously recalcitrant diseases.
A computational approach developed by researchers at MD Anderson Cancer Center combines data from parallel gene-expression profiling methods to create spatial maps of a given tissue at single-cell resolution. The resulting maps can provide insights into the cancer microenvironment and other tissue types.
A study led by researchers from MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
